Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study
designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in
participants diagnosed with mild to moderate Alzheimer's disease.